SEC Form SC 13G filed by Kazia Therapeutics Limited
$KZIA
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2021 | $18.00 | Buy | Maxim Group |
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
NT 20-F - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY, Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM. In July 2024, the Company announced results from the Ph
Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably to historical response rates for whole brain radiation therapy alone SYDNEY, Oct. 2, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation
SYDNEY, Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington. Dr. John Friend, CEO Kazia Therapeutics presented preliminary data from a Phase 1 first-in-
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
Shares of SolarEdge Technologies, Inc. (NASDAQ:SEDG) fell sharply during Monday's session after the company announced a workforce reduction. SolarEdge disclosed a decision to lay off 400 employees. The company stated that 200 of these job cuts are in Israel. The action involves reducing headcount and discretionary spending across all departments. SolarEdge Technologies shares dipped 12.2% to $27.77 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Autonomix Medical, Inc. (NASDAQ:AMIX) shares climbed 148% to $1.4850 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Gener
U.S. stocks traded higher toward the end of trading, with the Dow Jones index surging past the 40,000 mark on Friday. The Dow traded up 1.09% to 40,187.34 while the NASDAQ rose 1.30% to 18,521.69. The S&P 500 also rose, gaining, 1.12% to 5,647.26. Check This Out: This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Leading and Lagging SectorsInformation technology shares jumped by 1.5% on Friday. In trading on Friday, communication services shares fell by 0.2%. Top Headline Citigroup Inc (NYSE:C) reported better-than-expected results for its second quarter. The bank posted a second-quarter fiscal 2024 revenue growth of 4% year-ov
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer
SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin